Amneal Pharma acquires Punishka Healthcare for Rs 700 Cr

U.S based Amneal Pharmaceuticals has announced acquisition of India’s global injectable firm Punishka Healthcare. The acquisition worth $93 million, or approximately Rs 700 crore significantly enhances Amneal’s injectables manufacturing infrastructure, capabilities, and capacity to support the US market and serve as a foundation for international markets. Punishka Healthcare includes a 293,000 sq ft, state-of-theart manufacturing facility in Ahmedabad with a number of sterile injectable production lines. Production capabilities include robotic, aseptic and lyophilised vial lines, emulsion line, and large-volume parenteral bag line. The acquisition also brings to Amneal approximately 550 Punishka employees with key capabilities in injectables manufacturing, R&D and commercialisation. Since establishing local operations in 2008, Amneal has built a large and growing presence in India through over $300 million of capital investments and acquisitions. With Punishka, the company employs more than 4,500 talented employees to support its core global manufacturing and R&D functions across eight facilities in India.